Four Daiichi Sankyo Blood-Pressure Drugs Given U.S. FDA Warning
This article was originally published in PharmAsia News
Four Daiichi Sankyo blood-pressure drugs received warnings from U.S. FDA, which said they can cause severe adverse reactions, some leading to hospitalization.
You may also be interested in...
After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.